Indication intelligence, analysis and sector perception

Juno Therapeutics (JUNO) proposes $225 M follow-on offering

September 20, 2017 6:16pm

Shares closed up +$1.41 or +3.22 to $45.21 while the aftermarket drops -$1.95 or -4.31%

106,32 M shares outstanding a float of 70.66 M and a BIG shirt position of 15.43 M shares and 697.62 M in cash, 10 M indebtbut 82,57 M in revenue

Juno Therapeutics Inc. (JUNO) fell after the biopharmaceutical company announced the launch of a proposed follow-on public offering worth $225 million.

Juno said it expects to grant the underwriters an option to purchase up to an additional $33.75 million of shares. The company plans on using the proceeds for … the usual, general corporate purposes and working capital, Juno said in a statement.

Morgan Stanley and J.P. Morgan are joint book runners. The stock ended the regular trading session up 3.2%.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.